Xconomy: San Francisco blog main News, Articles and Opinions

Results for “”

Entry	Author	Date	Location
Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More	Alex Lash	09/20/19	National
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?	Alex Lash	09/19/19	National
Why Menlo Ventures Backed Construction Tech Firm Fieldwire	Bernadette Tansey	09/16/19	San Francisco
Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA	Frank Vinluan	09/13/19	San Francisco
Cloudflare’s $525M IPO Emboldens Already-Confident Internet Booster	David Holley	09/13/19	San Francisco
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More	Ben Fidler	09/13/19	National
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M	Frank Vinluan	09/12/19	San Francisco
John Halamka, Livongo Health & AI Progress at X·CON on Oct. 22	Jeff Bauter Engel	09/12/19	Boston
FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb	Frank Vinluan	09/11/19	San Francisco
After First Look at House Drug Plan, Stocks Rise Slightly	Alex Lash	09/10/19	National
Herceptin Inventors, Immunology Pioneers Take Home 2019 Lasker Awards	Ben Fidler	09/10/19	National
Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System	Frank Vinluan	09/10/19	San Francisco
As New CEO of Cerevel, Coles Moves From One Neuro Startup to Another	Ben Fidler	09/09/19	Boston
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More	Ben Fidler	09/09/19	National
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds	Frank Vinluan	09/06/19	Boston
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone	Frank Vinluan	09/06/19	National
SF’s Ginger Raises $35M in Burgeoning Digital Therapeutics Market	Jeff Buchanan	09/04/19	San Francisco
Bankrupt uBiome Says Founders May Have Misled Investors	Alex Lash	09/04/19	San Francisco
Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs	Frank Vinluan	09/03/19	San Francisco
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing	Ben Fidler	09/02/19	New York
Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet	Frank Vinluan	08/30/19	Boston
Robocalls Crowd Out Real Business Calls. This Startup Has an Answer.	David Holley	08/30/19	Seattle
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More	Alex Lash	08/30/19	National
$5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop	Ben Fidler	08/29/19	Detroit Ann Arbor
ThoughtSpot Nabs $248M for Accessible Analytics, Nears $2B Valuation	Bernadette Tansey	08/28/19	San Francisco
Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal	Frank Vinluan	08/26/19	New York
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)	Alex Lash	08/26/19	National
VMware: “We Bought Carbon Black for $2.1B!” Analysts: “Oh… Why?”	Brian Dowling	08/23/19	Boston
GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug	Frank Vinluan	08/23/19	National
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More	Frank Vinluan	08/23/19	National
Page 1 of 195	next page »